Speaker(s): 

Adrianna Aziz Pharmacy Intern, Geisinger Student - has nothing to disclose.

Elayna Haring Pharmacy Intern, Geisinger Student - has nothing to disclose.

Moderator(s): 

Christopher DeFrancesco, PharmD, Clinical Pharmacist / Asst Pharmacy Residency Program Director Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Define the role of semaglutide therapy in patients with MASH/MASLD 

• Identify patient specific criteria for the use of semaglutide in patients with MASH/MASLD 

• Compare the use of Semaglutide in the 2023 AASLD guidelines to the updated 2025 AASLD guidelines. 

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Christopher DeFrancesco PharmD, RPH; Anil Singh MD; Roop Parlapalli, MD, FHM, FACP; Carolyn Chilewshi, PA-C; Emilie Detweiler, PharmD, RPh; Alexa Kerecman, CRNP; John Sacino, CPhT, and Miranda Steigler, PharmD, RPh have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None.